Savjetodavno povjerenstvo za industrijske promjene (CCMI) - Related Opinions

The opinion will provide few but meaningful and concrete recommendations, reflecting the contributions made in the sections' and CCMI own-initiative opinions addressing the Blue Deal from their respective perspectives.

The Covid 19-pandemic has drawn attention to the role of the pharmaceutical industry and to production, availability and affordability of medicines and medicinal products on the European market.

Dependency on critical ingredients, such as active pharmaceutical ingredients (APIs), became obvious when China and India limited exports. According to current data, up to 80% of APIs used in Europe and about 40% of finished medicines sold in Europe come from China or India. The European Union's increasing dependence on API supplies has led to a partial loss of capability to manufacture active substances independently, which poses a potential threat to public health in the countries of the European Union.

The European Union has close to 182 million hectares of forests covering 43% of its land area and these forest areas are one of Europe's most important renewable resources. EU forests are exceptionally diverse, with a large variety of forest types, characteristics and ownership structures. They provide multiple benefits for society and the economy whilst being a major source of biodiversity.